Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | PDE5A | O76074 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14869469 | 0.90 | KCNH2 (0.52) | KCNH2L3MBTL1MEN1KMT2AHDAC3 | |
| SCHEMBL14869475 | 0.87 | BCDIN3D (0.53) | MEN1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL2451349 | 0.87 | LMNA (0.56) | KCNH2L3MBTL1MEN1KMT2AHDAC3 | |
| SCHEMBL15100680 | 0.85 | KCNH2 (0.43) | KCNH2L3MBTL1MEN1KMT2AHDAC3 | |
| SCHEMBL22214956 | 0.82 | KCNH2 (0.54) | KCNH2L3MBTL1MEN1KMT2AHDAC3 | |
| SCHEMBL22533770 | 0.81 | L3MBTL1 (0.50) | L3MBTL1MEN1KMT2ANPC1LMNA | |
| SCHEMBL15100696 | 0.79 | MAPT (0.48) | KCNH2MEN1KMT2ANPC1LMNA | |
| SCHEMBL31456247 | 0.79 | ADORA3 (0.57) | ALDH1A1HPGDTSHRMAPTKDM4E | |
| SCHEMBL14869395 | 0.79 | BCDIN3D (0.52) | KCNH2MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL14869450 | 0.79 | BCDIN3D (0.52) | MEN1KMT2ALMNAALDH1A1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197858-B1 | 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO LTD (KR) | 2014-07-02 | — | — | EP | claimed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2020-05-07 | — | — | US | disclosed |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2019-03-14 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-11-20 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2197858-B1 | 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO LTD (KR) | 2014-07-02 | — | — | EP | disclosed |
| US-8722674-B2 | 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-05-13 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20110237587-A1 | 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same | HANALL PHARMACEUTICAL COMPANY, LTD (KR) | 2011-09-29 | — | — | US | disclosed |
| EP-2197858-A2 | 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Hanall Pharmaceutical Company LTD. (KR) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009028891-A2 | 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL PHARMACEUTICAL COMPANY. LTD (KR) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237587-A1 | 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same | TP53, TP53BP1, SLC5A1 | KCNH2 3392/4885L3MBTL1 1450/4885MEN1 715/4885 |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | KCNH2 1551/4885L3MBTL1 4566/4885MEN1 679/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | KCNH2 1551/4885L3MBTL1 4566/4885MEN1 679/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | KCNH2 1551/4885L3MBTL1 4566/4885MEN1 679/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | KCNH2 1551/4885L3MBTL1 4566/4885MEN1 679/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | KCNH2 1551/4885L3MBTL1 4566/4885MEN1 679/4885 |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | KCNH2 1551/4885L3MBTL1 4566/4885MEN1 679/4885 |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | KCNH2 1551/4885L3MBTL1 4566/4885MEN1 679/4885 |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | KCNH2 1385/4885L3MBTL1 4487/4885MEN1 493/4885 |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | KCNH2 1551/4885L3MBTL1 4566/4885MEN1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.